{"title":"在首次人体试验中，细胞外靶向蛋白降解器清除了抗体。","authors":"Asher Mullard","doi":"10.1038/d41573-024-00103-6","DOIUrl":null,"url":null,"abstract":"Biohaven’s BHV-1300 lowered levels of immunoglobulin G in the blood of healthy volunteers — a first clinical demonstration of the potential of a small-molecule extracellular protein degrader. Biohaven’s BHV-1300 lowered levels of immunoglobulin G in the blood of healthy volunteers — a first clinical demonstration of the potential of a small-molecule extracellular protein degrader.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"23 7","pages":"483-486"},"PeriodicalIF":101.8000,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Extracellular targeted protein degrader removes antibodies in first test in humans\",\"authors\":\"Asher Mullard\",\"doi\":\"10.1038/d41573-024-00103-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Biohaven’s BHV-1300 lowered levels of immunoglobulin G in the blood of healthy volunteers — a first clinical demonstration of the potential of a small-molecule extracellular protein degrader. Biohaven’s BHV-1300 lowered levels of immunoglobulin G in the blood of healthy volunteers — a first clinical demonstration of the potential of a small-molecule extracellular protein degrader.\",\"PeriodicalId\":19068,\"journal\":{\"name\":\"Nature Reviews. Drug Discovery\",\"volume\":\"23 7\",\"pages\":\"483-486\"},\"PeriodicalIF\":101.8000,\"publicationDate\":\"2024-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews. Drug Discovery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/d41573-024-00103-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews. Drug Discovery","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/d41573-024-00103-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
Biohaven 的 BHV-1300 降低了健康志愿者血液中免疫球蛋白 G 的水平--首次临床验证了小分子细胞外蛋白降解剂的潜力。Biohaven 的 BHV-1300 降低了健康志愿者血液中免疫球蛋白 G 的水平，首次在临床上展示了小分子细胞外蛋白降解剂的潜力。
Extracellular targeted protein degrader removes antibodies in first test in humans
Biohaven’s BHV-1300 lowered levels of immunoglobulin G in the blood of healthy volunteers — a first clinical demonstration of the potential of a small-molecule extracellular protein degrader. Biohaven’s BHV-1300 lowered levels of immunoglobulin G in the blood of healthy volunteers — a first clinical demonstration of the potential of a small-molecule extracellular protein degrader.
期刊介绍：
Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena.
Each issue includes:
Highest-quality reviews and perspectives covering a broad scope.
News stories investigating the hottest topics in drug discovery.
Timely summaries of key primary research papers.
Concise updates on the latest advances in areas such as new drug approvals, patent law, and emerging industry trends and strategies.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
